A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivo

• Main Authors: Min You (Author), Fentian Chen (Author), Chao Yu (Author), Yuanzhi Chen (Author), Yue Wang (Author), Xue Liu (Author), Xueran Guo (Author), Bing Zhou (Author), Xin Wang (Author), Boya Zhang (Author), Mujin Fang (Author), Tianying Zhang (Author), Ping Yue (Author), Yingbin Wang (Author), Quan Yuan (Author), Wenxin Luo (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: The effective and persistent suppression of hepatitis B surface antigen (HBsAg) in patients with chronic HBV infection (CHB) is considered to be a promising approach to achieve a functional cure of hepatitis B. In our previous study, we found that the antibody E6F6 can clear HBsAg thro...